Answers are grounded in this paper and cite their sources.
User-fee reauthorization creates new opportunities for the FDA to address issues with its accelerated-approval program, including the lack of evidence of clinical benefit for some products.
No takes yet. Share an insight, caveat, or question.
Sachs et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: